1,593 results on '"Nakanishi, Yoichi"'
Search Results
202. Frequency of Foxp3+CD4+CD25+ T cells is associated with the phenotypes of allergic asthma
203. Serum surfactant protein D is increased in acute and chronic inflammation in mice
204. Cardiac, pulmonary and renal function in Yusho patients
205. Detection of group C adenovirus DNA in small-cell lung cancer with the nested polymerase chain reaction
206. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines
207. A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-Naïve Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer
208. CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung, and the diminished expression significantly harms outcomes
209. The Role of High Mobility Group Box1 in Pulmonary Fibrosis
210. Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice
211. Protection Against the Extravasation of Anticancer Drugs by Standardization of the Management System
212. 38. IN VIVO ANTITUMOR VACCINE EFFECTS OF NONTRANSMISSIBLE SEV ENCODING GM-CSF IN MOUSE RENAL CELL CARCINOMA MODELS
213. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer
214. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis
215. MOESM2 of Effects of cigarette smoke on barrier function and tight junction proteins in the bronchial epithelium: protective role of cathelicidin LL-37
216. Granulocyte-colony stimulating factor promotes invasion by human lung cancer cell lines in vitro
217. Proton pumps of the vacuolar membrane in growing plant cells
218. Academia–industry Cooperation in the Medical Field: Matching Opportunities in Japan
219. Intellectual Property in the Field of Regenerative Medicine in Japan
220. Effects of Salmeterol in Patients with Persistent Asthma Receiving Inhaled Corticosteroid plus Theophylline
221. H+-ATPase and H+-PPase in the Vacuolar Membrane
222. Effects of Salmeterol in Patients with Persistent Asthma Receiving Inhaled Corticosteroid Plus Theophylline: O-9-1
223. Prevention of Radiation-induced Pneumonitis by Recombinant Adenovirus-mediated Transferring of Soluble TGF-β Type II Receptor Gene: O-6-5
224. Randomized Phase Ii Study of Carboplatin/Gemcitabine Versus Vinorelbine/Gemcitabine in Patients With Advanced Nonsmall Cell Lung Cancer: West Japan Thoracic Oncology Group (WJTOG) 0104
225. Niflumic Acid Suppresses Interleukin-13-induced Asthma Phenotypes
226. Expression of Functional Streptomyces coelicolor H+-Pyrophosphatase and Characterization of Its Molecular Properties
227. Different roles of interleukin-10 in onset and resolution of asthmatic responses in allergen-challenged mice
228. Serum CC-10 in Inflammatory Lung Diseases
229. Functional expression of Acetabularia acetabulum vacuolar H+-pyrophosphatase in a yeast VMA3-deficient strain1
230. A case of extrapleural empyema
231. Expression of V-ATPase proteolipid subunit of Acetabularia acetabulum in a VMA3-deficient strain of Saccharomyces cerevisiae and study of its complementation
232. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma
233. Polycyclic Aromatic Hydrocarbon Carcinogens Increase Ubiquitination of p21 Protein after the Stabilization of p53 and the Expression of p21
234. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma
235. Prognosis of Bronchial Artery Embolization in the Management of Hemoptysis
236. Frequent Expression of p53 Protein without Mutation in the Atypical Epithelium of Human Bronchus
237. Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)
238. Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401
239. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab‐Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non‐Small Cell Lung Cancer
240. Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer
241. Involvement of GPx4-Regulated Lipid Peroxidation in Idiopathic Pulmonary Fibrosis Pathogenesis
242. Development of Systemic Musculoarticular Sarcoidosis 30 Years After Onset of Cutaneous Sarcoidosis
243. Current progress and issues of cancer genomic medicine in Kyushu University Hospital
244. Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors
245. Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer
246. Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L)
247. Updated survival date of phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
248. Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L).
249. A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).
250. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.